Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Precision Medicine Institute
Colleague Insights
Video Expert Opinion
Resource Library
Conferences
Tumor Boards
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Lung Cancer and
1 other channel

Journal Scan / Research · December 01, 2022

Patient-Reported Outcomes Following First-Line Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC

Lung Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Lung Cancer
Patient-Reported Outcomes From the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer
Lung Cancer 2022 Dec 01;174(xx)146-156, J Mazieres, L Iadeluca, AT Shaw, et al

Further Reading

Recently Updated